Results For "mAbxience"

3 News Found

Amneal and mAbxience score FDA green light for two Denosumab biosimilars

Drug Approval | December 27, 2025

Amneal and mAbxience score FDA green light for two Denosumab biosimilars

Cipla Medpro South Africa partners with mAbxience for affordable cancer drugs

News | March 31, 2022

Cipla Medpro South Africa partners with mAbxience for affordable cancer drugs

The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication

Amneal achieves second U.S. biosimilars approval with Alymsys

Drug Approval | April 18, 2022

Amneal achieves second U.S. biosimilars approval with Alymsys

Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022

Latest Stories

InnoCare Pharma gets green light for Phase II trial of oral lupus drug

Ginkgo Bioworks teams with Carnegie Mellon on cancer detection program

FDA setback for Sanofi’s Tolebrutinib in progressive MS

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging